Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio

Chinese Medical Journal

Volumn 126, Issue 11, 2013, Pages 2149-2156

  An, Zhe ^a   Yang, Guang ^b   He, Yu Quan ^a   Dong, Ning ^c   Ge, Li Li ^a   Li, Shu Mei ^a   Zhang, Wen Qi ^a  

^a JILIN UNIVERSITY   (China)

^b Jilin University   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Atorvastatin; Cardiac fibroblasts; Matrix metalloproteinase 2; Tissue matrix metalloproteinase inhibitor 2

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HISTOLOGY; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; HEART FAILURE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; MYOCARDIUM; PYRROLES; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VENTRICULAR REMODELING;

EID: 84878693811     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123223     Document Type: Article

References (30)

1. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011; 4: 98-108.
2. Palazzuoli A, Nuti R. Heart failure: pathophysiology and clinical picture. Contrib Nephrol 2010; 164: 1-10.
3. Cokkinos DV, Pantos C. Myocardial remodeling, an overview. Heart Fail Rev 2011; 16: 1-4.
4. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359.
5. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: Embracing the MMP-independent-side of the family. J Mol Cell Cardiol 2010; 48: 445-453.
6. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2012; 17: 693-706.
7. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 2011; 124: 2094-2105.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
9. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5: 81-87.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
11. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation 2002; 105: 2937-2938.
12. Uhiara CO, Alexander SP, Roberts RE. Simvastatin evokes an unpredicted inhibition of β-adrenoceptor-mediated vasodilatation in porcine coronary artery. Eur J Pharmacol 2012; 690: 158-163.
13. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56: 53-56.
14. Luzak B, Rywaniak J, Stanczyk L, Watala C. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. Eur J Clin Invest 2012; 42: 864-972.
15. Kückelhaus CS, Kückelhaus SA, Muniz-Junqueira MI. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis. Exp Parasitol 2011; 127: 658-664.
16. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004: 93: 1124-1129.
17. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873.
18. Muñoz V, Grzeda KR, Desplantez T, Pandit SV, Mironov S, Taffet SM, et al. Adenoviral expression of IKs contributes to wavebreak and fibrillatory conduction in neonatal rat ventricular cardiomyocyte monolayers. Circ Res 2007; 101: 475-483.
19. Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc 2012; 87: 555-560.
20. Song XJ, Yang CY, Liu B, Wei Q, Korkor MT, Liu JY, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci 2011; 8: 564-572.
21. Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, et al. Benefits of statin therapy based on plasma carbohydrate antigen 125 values following an admission for acute heart failure. Rev Esp Cardiol 2011; 64: 1100-1108.
22. Ouzounian M, Tu JV, Austin PC, Chong A, Liu PP, Lee DS. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail 2009; 15: 241-248.
23. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Poloński L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97: 899-904.
24. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-337.
25. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005; 32: 697-701.
26. Tsuruda T, Kato J, Eto T. Effect of adrenomedullin on cardiac myocytes and fibroblasts. Nihon Rinsho 2004; 9: 233-236.
27. Tian JW, Zhao LY, Wang SW, Zhang HT, Zheng QS, Yang XD, et al. Effects of atorvastatin on the proliferation and collagen synthesis of rat cardiac fibroblasts. Natl Med J China (Chin) 2003; 83: 118-122.
28. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007; 9: 546-550.
29. Polyakova V, Loeffler I, Hein S, Miyagawa S, Piotrowska I, Dammer S, et al. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol 2011; 151: 18-33.
30. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE. Effects of statins on matrix metallo proteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 547-554.